SI2849798T1 - Oligonukleotidni kelatni kompleksni polipeptidni sestavki in postopki - Google Patents

Oligonukleotidni kelatni kompleksni polipeptidni sestavki in postopki

Info

Publication number
SI2849798T1
SI2849798T1 SI201331881T SI201331881T SI2849798T1 SI 2849798 T1 SI2849798 T1 SI 2849798T1 SI 201331881 T SI201331881 T SI 201331881T SI 201331881 T SI201331881 T SI 201331881T SI 2849798 T1 SI2849798 T1 SI 2849798T1
Authority
SI
Slovenia
Prior art keywords
methods
chelate complex
polypeptide compositions
oligonucleotide chelate
oligonucleotide
Prior art date
Application number
SI201331881T
Other languages
English (en)
Slovenian (sl)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2849798(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc. filed Critical Replicor Inc.
Publication of SI2849798T1 publication Critical patent/SI2849798T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
SI201331881T 2012-05-18 2013-05-17 Oligonukleotidni kelatni kompleksni polipeptidni sestavki in postopki SI2849798T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
EP13791618.5A EP2849798B1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
SI2849798T1 true SI2849798T1 (sl) 2021-08-31

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331881T SI2849798T1 (sl) 2012-05-18 2013-05-17 Oligonukleotidni kelatni kompleksni polipeptidni sestavki in postopki

Country Status (34)

Country Link
US (1) US9492506B2 (cg-RX-API-DMAC7.html)
EP (1) EP2849798B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015517504A (cg-RX-API-DMAC7.html)
KR (1) KR102068109B1 (cg-RX-API-DMAC7.html)
CN (1) CN104349793B (cg-RX-API-DMAC7.html)
AU (1) AU2013262416B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014028654A2 (cg-RX-API-DMAC7.html)
CA (1) CA2873529C (cg-RX-API-DMAC7.html)
CL (1) CL2014003134A1 (cg-RX-API-DMAC7.html)
CO (1) CO7131387A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140527A (cg-RX-API-DMAC7.html)
CY (1) CY1124345T1 (cg-RX-API-DMAC7.html)
DK (1) DK2849798T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000264A (cg-RX-API-DMAC7.html)
EA (1) EA035967B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14027694A (cg-RX-API-DMAC7.html)
ES (1) ES2873844T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210840T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054875T2 (cg-RX-API-DMAC7.html)
IL (1) IL235548B (cg-RX-API-DMAC7.html)
LT (1) LT2849798T (cg-RX-API-DMAC7.html)
MX (1) MX346239B (cg-RX-API-DMAC7.html)
MY (1) MY168778A (cg-RX-API-DMAC7.html)
NZ (1) NZ703095A (cg-RX-API-DMAC7.html)
PH (1) PH12014502551B1 (cg-RX-API-DMAC7.html)
PL (1) PL2849798T3 (cg-RX-API-DMAC7.html)
PT (1) PT2849798T (cg-RX-API-DMAC7.html)
RS (1) RS62030B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201407599SA (cg-RX-API-DMAC7.html)
SI (1) SI2849798T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100319T1 (cg-RX-API-DMAC7.html)
TW (1) TWI635864B (cg-RX-API-DMAC7.html)
WO (1) WO2013170386A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408674B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2158316T3 (pl) 2007-05-11 2015-10-30 Adynxx Inc Ekspresja genowa oraz ból
AU2013259402B2 (en) 2012-05-10 2017-12-21 Adynxx, Inc. Formulations for the delivery of active ingredients
TWI620568B (zh) 2012-08-30 2018-04-11 雷普利可公司 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
MX381042B (es) 2014-07-10 2025-03-12 Replicor Inc Uso de un complejo quelato y un anàlogo de neucleòsido o neucleòtido para tratar infecciones de virus de la hepatitis b y hepatitis d.
EP3180434B1 (en) 2014-08-15 2019-07-17 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
SG11202104636XA (en) * 2018-11-08 2021-06-29 Aligos Therapeutics Inc S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
BR0314236A (pt) * 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
JP2006519235A (ja) 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
KR20060120162A (ko) * 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Ｈｃｖ 치료용 배합물
EP1802643A1 (en) 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1928498A4 (en) * 2005-09-29 2009-11-11 Cell Biosciences Inc S METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
WO2007036016A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2008334948B2 (en) 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
US8361980B2 (en) * 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
CA2764683A1 (en) * 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CN102762215A (zh) * 2009-10-16 2012-10-31 葛兰素集团有限公司 Hbv反义抑制剂
SG187165A1 (en) * 2010-08-20 2013-02-28 Replicor Inc Oligonucleotide chelate complexes
TWI620568B (zh) 2012-08-30 2018-04-11 雷普利可公司 用於治療ｂ型肝炎及ｄ型肝炎感染之方法

Also Published As

Publication number Publication date
CA2873529A1 (en) 2013-11-21
SMT202100319T1 (it) 2021-09-14
EP2849798A4 (en) 2016-03-09
CY1124345T1 (el) 2022-07-22
AU2013262416A1 (en) 2014-12-18
MY168778A (en) 2018-12-04
LT2849798T (lt) 2021-08-10
CN104349793B (zh) 2017-11-10
HUE054875T2 (hu) 2021-10-28
MX346239B (es) 2017-03-13
KR20150013309A (ko) 2015-02-04
EA035967B1 (ru) 2020-09-07
HK1204279A1 (en) 2015-11-13
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
US20130309201A1 (en) 2013-11-21
CR20140527A (es) 2014-12-15
TWI635864B (zh) 2018-09-21
TW201408308A (zh) 2014-03-01
CO7131387A2 (es) 2014-12-01
EP2849798B1 (en) 2021-04-07
RS62030B1 (sr) 2021-07-30
PL2849798T3 (pl) 2021-10-18
AU2013262416B2 (en) 2017-05-11
WO2013170386A1 (en) 2013-11-21
NZ703095A (en) 2016-07-29
DK2849798T3 (da) 2021-05-31
EA201401278A1 (ru) 2015-04-30
KR102068109B1 (ko) 2020-01-21
CN104349793A (zh) 2015-02-11
US9492506B2 (en) 2016-11-15
EP2849798A1 (en) 2015-03-25
CA2873529C (en) 2020-08-18
PH12014502551B1 (en) 2019-10-11
IL235548B (en) 2019-07-31
HRP20210840T1 (hr) 2021-08-06
PH12014502551A1 (en) 2015-01-21
DOP2014000264A (es) 2015-01-31
CL2014003134A1 (es) 2015-02-13
JP2015517504A (ja) 2015-06-22
MX2014014021A (es) 2015-02-10
ES2873844T3 (es) 2021-11-04
ZA201408674B (en) 2016-01-27
SG11201407599SA (en) 2014-12-30
PT2849798T (pt) 2021-05-18
ECSP14027694A (es) 2015-12-31

Similar Documents

Publication Publication Date Title
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL233649A0 (en) Preparations derived from chitosan
EP2852602A4 (en) COMPOSITIONS AND METHODS FOR CONJUGATING OLIGONUCLEOTIDES
ZA201408082B (en) Oligonucleotide chelate complex methods
ZA201408674B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
GB2511197B (en) Compositions
GB201315350D0 (en) Methods and compositions
GB201210800D0 (en) Compositions
GB201209244D0 (en) Compositions
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB201201287D0 (en) Compositions
GB201220068D0 (en) Compositions
ZA201502542B (en) Compositions
GB201219962D0 (en) Compositions
GB201219980D0 (en) Compositions
TWI561248B (en) Peracid-generating compositions
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201116340D0 (en) Compositions and methods
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions
GB201218959D0 (en) Compositions
GB201209189D0 (en) Compositions
GB201204102D0 (en) Compositions